MDxHealth SA has 6 Schedule 13D or 13G filings on record since 2025-11-14. 3 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Bleichroeder LP | 33.2% | 31,648,563 | SCHEDULE 13D, 2026-08-14 | 2026-08-11 |
| Laurence W. Lytton | 19.5% | 18,558,988 | SCHEDULE 13G/A, 2026-08-17 | 2026-08-13 |
| Genomic Health, Inc. | 12% | 6,441,171 | SCHEDULE 13G/A, 2026-01-16 | 2026-01-09 |
| AWM Investment Company, Inc. | 0% | 0 | SCHEDULE 13G/A, 2026-07-08 | 2026-06-30 |
Purpose of Transaction (Item 4)
Bleichroeder LP
Bleichroeder originally acquired beneficial ownership of Shares of the Issuer for investment purposes. On August 11, 2026, certain funds and entities managed by Bleichroeder (the "Funds") entered into securities purchase agreements with the Issuer (the "Securities Purchase Agreements") pursuant to which they purchased in the aggregate 24,229,074 Ordinary Shares (the "Purchased Shares") in a registered direct offering for a per-share purchase price of $0.454. On August 11, 2026, the Funds entered into a lock-up agreement (the "Lock-Up Agreement") with the Issuer pursuant to which, among other things, the Funds agreed not to sell, offer, pledge or otherwise dispose or transfer, or enter into any other agreement (including hedging transactions) that transfers the economic consequences of owning the Purchased Shares, subject to customary exceptions, for a period of 90 days from the date of the Security Purchase Agreements. The Reporting Persons intend to evaluate on an ongoing basis the investment in the Issuer and the options with respect to such investment. In connection with such evaluation, Bleichroeder may seek calls and meetings with members of the Board and/or senior management of the Issuer, or communicate publicly or privately with other stockholders, knowledgeable industry or market observers or other third parties to indicate Bleichroeder's views on issues relating to the strategic direction undertaken by the Issuer and other matters of interest to stockholders …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-14; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Lytton Laurence W | 6.4% | SCHEDULE 13G/A |
| 2026-01-16 | Genomic Health, Inc. | 12% | SCHEDULE 13G/A |
| 2026-07-08 | AWM Investment Company, Inc. | 0% | SCHEDULE 13G/A |
| 2026-08-13 | Lytton Laurence W | 9.6% | SCHEDULE 13G/A |
| 2026-08-14 | Bleichroeder LP | 33.2% | SCHEDULE 13D |
| 2026-08-17 | Laurence W. Lytton | 19.5% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for MDxHealth SA. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.